Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: An open-label trial in drug-free patients with bipolar disorder

Journal of Psychiatric Research

Volumn 46, Issue 11, 2012, Pages 1511-1514

  Grande, Iria ^a   Kapczinski, Flávio ^b   Stertz, Laura ^b   Colpo, Gabriela Delevatti ^b   Kunz, Mauricio ^b   Cereser, Keila Mendes ^b   Kauer Sant'Anna, Marcia ^b   Frey, Benicio ^c   Vieta, Eduard ^a   Magalhaes, Pedro V S ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

BDNF; Biomarkers; Bipolar disorder; Brain derived neurotrophic factor; Depression; Mania; Treatment response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; QUETIAPINE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DRUG EFFECT; DRUG RELEASE; FEMALE; HAMILTON SCALE; HUMAN; LONGITUDINAL STUDY; MALE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; OPEN STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

EID: 84866950805     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.08.017     Document Type: Article

References (42)

1. Andreazza A.C., Frey B.N., Erdtmann B., Salvador M., Rombaldi F., Santin A., et al. DNA damage in bipolar disorder. Psychiatry Research 2007, 153:27-32.
2. Andreazza A.C., Kauer-Sant'Anna M., Frey B.N., Bond D.J., Kapczinski F., Young L.T., et al. Oxidative stress markers in bipolar disorder: a meta-analysis. Journal of Affective Disorders 2008, 111:135-144.
3. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews 2012, 64:238-258.
4. Berk M., Brnabic A., Dodd S., Kelin K., Tohen M., Malhi G.S., et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disorders 2011, 13:87-98.
5. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & Biobehavioral Reviews 2011, 35:804-817.
6. Chiesa A., Chierzi F., De Ronchi D., Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. International Clinical Psychopharmacology 2012, 27:76-90.
7. Conus P., Cotton S., Abdel-Baki A., Lambert M., Berk M., McGorry P.D. Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders 2006, 8:221-231.
8. Duman R.S. Synaptic plasticity and mood disorders. Molecular Psychiatry 2002, 7(Suppl. 1):S29-S34.
9. Fernandes B.S., Gama C.S., Ceresér K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. Journal of Psychiatric Research 2011, 45:995-1004.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders, research version, patient edition (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
11. Fumagalli F., Molteni R., Bedogni F., Gennarelli M., Perez J., Racagni G., et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 2004, 15:2109-2112.
12. Grande I., Fries G.R., Kunz M., Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investigation 2010, 7:243-250.
13. Grande I., Magalhães P.V., Kunz M., Vieta E., Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiology & Behavior 2012, 106:46-50.
14. Guy W. ECDEU assessment manual for psychopharmacology 1976, U.S. Department of Health, Education and Welfare, Rockvile, MD.
15. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V.S., Kauer-Sant'Anna M., Klamt F., et al. Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research 2011, 45:156-161.
16. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters 2002, 328:261-264.
17. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology 2009, 12:447-458.
18. Lang U.E., Hellweg R., Seifert F., Schubert F., Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biological Psychiatry 2007, 62:530-535.
19. López-Jaramillo C., Lopera-Vásquez J., Gallo A., Ospina-Duque J., Bell V., Torrent C., et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disorders 2010, 12:557-567.
20. Luo C., Xu H., Li X.-M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Research 2005, 1063:32-39.
21. Magalhães P.V., Kapczinski F., Nierenberg A.A., Deckersbach T., Weisinger D., Dodd S., et al. Illness burden and medical comorbidity in the systematic treatment enhancement program for bipolar disorder. Acta Psychiatrica Scandinavica 2012, 125:303-308.
22. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., et al. Impaired mitochondrial function in psychiatric disorders. Nature Reviews. Neuroscience 2012 Apr. 18, [Epub ahead of print]. 10.1038/nrn3229.
23. McIntyre R.S., Soczynska J.K., Woldeyohannes H.O., Alsuwaidan M., Konarski J.Z. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opinion on Pharmacotherapy 2007, 8:1211-1219.
24. Palomino A., Vallejo-Illarramendi A., González-Pinto A., Aldama A., González-Gómez C., Mosquera F., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophrenia Research 2006, 86:321-322.
25. Park S.-W., Lee S.-K., Kim J.-M., Yoon J.-S., Kim Y.-H. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neuroscience Letters 2006, 402:25-29.
26. Post R.M. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. Journal of Psychiatric Research 2007, 41:979-990.
27. Rosa A.R., González-Ortega I., González-Pinto A., Echeburúa E., Comes M., Martínez-àran A., et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatrica Scandinavica 2012, 125:335-341.
28. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
29. Sole B., Bonnin C.M., Torrent C., Martinez-Aran A., Popovic D., Tabarés-Seisdedos R., et al. Neurocognitive impairment across the bipolar spectrum. CNS Neuroscience & Therapeutics 2012, 18:194-200.
30. Tamayo J.M., Zarate C.A., Vieta E., Vázquez G., Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology 2010, 13:813-832.
31. Tohen M., Frank E., Bowden C.L., Colom F., Ghaemi S.N., Yatham L.N., et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders 2009, 11:453-473.
32. Torrent C., Martinez-Arán A., Daban C., Amann B., Balanzá-Martínez V., del Mar Bonnín C., et al. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Comprehensive Psychiatry 2011, 52:613-622.
33. Tramontina J.F., Andreazza A.C., Kauer-Sant'Anna M., Stertz L., Goi J., Chiarani F., et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neuroscience Letters 2009, 452:111-113.
34. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Human Psychopharmacology: Clinical & Experimental 2005, 20:225-236.
35. Vieta E., Locklear J., Günther O., Ekman M., Miltenburger C., Chatterton M.L., et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 2010, 30:579-590.
36. Willett J.B., Singer J.D., Martin N.C. The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Development and Psychopathology 1998, 10:395-426.
37. Williams J.B. A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry 1988, 45:742-747.
38. Xu H., Chen Z., He J., Haimanot S., Li X., Dyck L., et al. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006, 16:551-559.
39. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 2009, 11:225-255.
40. Yoshimura R., Ikenouchi-Sugita A., Hori H., Umene-Nakano W., Katsuki A., Hayashi K., et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:308-312.
41. Yoshimura R., Mitoma M., Sugita A., Hori H., Okamoto T., Umene W., et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:1034-1037.
42. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. The British Journal of Psychiatry 1978, 133:429-435.